Literature DB >> 23187772

Prevention of graft-versus-host disease.

Ran Reshef1.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 23187772

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  3 in total

1.  A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.

Authors:  Johan Törlén; Olle Ringdén; Karin Garming-Legert; Per Ljungman; Jacek Winiarski; Kari Remes; Maija Itälä-Remes; Mats Remberger; Jonas Mattsson
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

Review 2.  Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Amr Nassar; Ghada Elgohary; Tusneem Elhassan; Zubeir Nurgat; Said Y Mohamed; Mahmoud Aljurf
Journal:  J Transplant       Date:  2014-10-27

3.  Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis.

Authors:  Karin Garming Legert; Olle Ringdén; Mats Remberger; Johan Törlén; Jonas Mattsson; Göran Dahllöf
Journal:  Oral Dis       Date:  2020-10-27       Impact factor: 3.511

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.